Cryoport, Inc. (CYRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 22.50 |
| Open | 22.39 |
| Bid | 23.08 x 900 |
| Ask | 23.13 x 800 |
| Day's Range | 22.28 - 23.26 |
| 52 Week Range | 15.63 - 45.36 |
| Volume | |
| Avg. Volume | 555,145 |
| Market Cap | 1.13B |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.19 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CYRX
Related Research
- CryoPort, Inc.BLFS: What does Argus have to say about BLFS?BIOLIFE SOLUTIONS INC has an Investment Rating of HOLD; a target price of $26.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat4 days agoArgus Research
- Zacks
Syneos Health (SYNH) Signs New Partnership With Cryoport
Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.
- PR Newswire
Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry focused on the pharmaceutical and cell and gene therapy markets, today announced a new strategic partnership with Syneos Health® (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. Both Cryoport and Syneos Health are world leading solutions companies with deep ex
- PR Newswire
Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer, will be presenting at the J.P. Morgan 41st Annual Healthcare conference, taking place from January 9 - 12, 2023 in San Francisco, CA. Mr. Shelton will be presenting on Thursday, January 12, 2023, at 8:15 a.m. PT (11:15 a.m. ET). Additionally, Mr. Shelton, Robert St
